Skip to main content

Table 1 Binding selectivity (geometric mean) of candidate podocalyxin antibodies compared with isotype control a

From: Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy

mAb name HUVEC MCF7 MDA-MB-231 T47D CAOV-3 OVCAR-3 OVCAR-10 A-172 HEK293
Isotype 489 657 477 697 767 629 653 644 446
PODOC1 44,611 60,805 91,909 1,498 48,817 16,502 2,834 169,600 28,225
PODOC2 3,231 1,962 26,513 2,036 37,683 9,189 645 49,862 459
PODOC3 2,103 9,399 2,939 818 10,472 8,355 1,803 181,211 3,869
PODOC4 113,144 15,161 143,135 34,559 125,223 29,862 564 333,980 2,679
PODOC5 40,490 25,055 80,312 1,853 31,657 9,824 1,756 172,233 27,144
PODOC6 994 1,239 4,744 2,685 1,670 1,350 1,165 2,760 485
PODOC7 21,700 22,330 57,626 1,010 37,668 11,058 2,539 278,032 13,886
PODOC8 23,207 45,707 1,950 566 52,200 8,805 2,731 263,842 5,056
  1. aHEK293, Human embryonic kidney 293 cells; HUVEC, Human umbilical vascular endothelial cells; mAb, Monoclonal antibody; PODOC, Podocalyxin antibody.